denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: AstraZeneca. Provided by Clinical Care Options, LLC
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Combination therapy, Antibody Therapy, Lymphomas, B Cell lymphoma, Chemotherapy, Diseases, Therapy sequence, Aggressive lymphoma, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Non-Biological therapies, Adverse Events
Hematology Disease Topics & Pathways:
Combination therapy, Antibody Therapy, Lymphomas, B Cell lymphoma, Chemotherapy, Diseases, Therapy sequence, Aggressive lymphoma, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Non-Biological therapies, Adverse Events
Friday, December 6, 2024: 11:00 AM-2:00 PM
Grand Hall D
(Manchester Grand Hyatt San Diego)
Chair:
Julie M. Vose, MD, MBA, University of Nebraska Medical Center
Disclosures:
Vose: Pfizer: Research Funding; GenMab: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Novartis: Honoraria.
Speakers:
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis
and
John P. Leonard, MD, Weill Cornell Medicine
Disclosures:
Kahl: BeiGene: Consultancy, Research Funding; ADCT: Consultancy; Lilly: Consultancy, Honoraria; AstraZeneca: Consultancy, Research Funding; Roche: Consultancy, Research Funding; AbbVie: Consultancy; Genentech: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria. Leonard: AbbVie, AstraZeneca, Astellas, Bayer, BeiGene,BMS, Calithera, Caribou Bioscences, Constellation, Eisai, Epizyme,GenMab, Grail, Incyte, Janssen, Karyopharm, Lilly, Merck, Mustang Bio, Novartis, Pfizer, Roche/Genentech, Seagen, Second Genome, Sutro, Treelin: Consultancy, Honoraria.
The care of patients with mantle cell lymphoma (MCL) is becoming increasingly complex with new indications for BTK inhibitors and emerging data transforming management strategies. CCO proudly presents this live interactive symposium, designed to equip clinicians with the knowledge and insights needed to confidently navigate the rapidly evolving landscape of MCL patient care. Engage directly with leading experts through Q&A sessions, patient case discussions, and review of a 2025 MCL treatment algorithm. These interaction with the panelests will enhance your understanding and application of cutting-edge treatments for both newly-diagnosed and R/R disease. Join us for a dynamic and informative experience that will empower you to implement the latest treatment advances in BTK inhibitors for MCL and improve patient outcomes.
See more of: Friday Satellite Symposia